Pfizer to improve paediatric medicines manufacturing

Pfizer is set to make an investment in its Discovery Park site in Sandwich, Kent, UK.

The funding will improve Pfizer’s patient-centric design and manufacturing capability for paediatric medicines in clinical trials.

The £5m financing is the latest in a series of investments made by the company totalling £36m since last year. It forms part of Pfizer’s ongoing strategy to invest in research and development (R&D).

The latest investment will enable scientists to explore methods of making medicines more palatable with flexible dosing for children.

Pfizer’s Sandwich site head Julian Thompson said: "This investment demonstrates Pfizer’s continuing focus on innovation in advanced manufacturing and highlights our patient first approach: ensuring that cutting-edge technology can be used to design and manufacture medicines for clinical trials that are palatable for children with the most serious illnesses.

"Today’s announcement builds on a series of investments we have made to this site over the last few years and further reinforces our commitment to progressing science here in the UK."

Kent County Council has provided an additional £5m through the East Kent Growth Fund. At present, more than 700 employees are based at Pfizer’s site in Sandwich, working across various functions.

Pfizer’s pharmaceutical science group houses small molecule pilot plant that manufactures medicines for use in clinical trials worldwide.

Last July, Pfizer announced a $465m investment to build an advanced sterile injectable pharmaceutical production facility in Michigan to strengthen its capability to produce and supply life-saving injectable medicines for patients worldwide. 

-----------------------------------------------------------------------
Editor's Note:

If you have any suggestion to the content, 

please email: Julia.Zhang@ubmsinoexpo.com